A new diagnostic tool, the Envisia Genomic Classifier, can help make doctors more confident and accurate in diagnosing…
Articles by Marisa Wexler, MS
RXC007, an investigational oral therapy for idiopathic pulmonary fibrosis (IPF), is showing favorable safety and pharmacological properties in an ongoing…
People with a familial history of short telomere syndrome (STS) — a disorder involving shortened telomeres, or chromosome “caps” —…
Syndax Pharmaceuticals and Incyte are forming a global partnership to develop and commercialize axatilimab, an investigational therapy for…
Cudetaxestat (BLD-0409), an investigational treatment for idiopathic pulmonary fibrosis (IPF) being developed by Blade Therapeutics, does not interact…
A trio of global companies is teaming up to develop an inhaled dry powder formulation of SF2523, an investigational…
A protein called PDIA3 is overactive in pulmonary fibrosis (PF), and contributes to the disease by driving the production…
The U.S. Food and Drug Administration (FDA) has authorized Blade Therapeutics to begin a Phase 1 clinical…
MyMD Pharmaceuticals has secured a 13th U.S. patent protecting its experimental therapy MYMD-1, which is being investigated as a…
Treatment with two approved antifibrotics did not lessen a risk of death in recently hospitalized idiopathic pulmonary fibrosis (IPF) patients,…